Ehsan Vaghefi

Growing up with a father who suffered preventable blindness is what inspired Dr. Ehsan Vaghefi’s mission to transform routine eye exams. Founded in 2019, Toku Eyes, offers comprehensive health screenings capable of detecting early signs of chronic illnesses like cardiovascular and kidney disease.

Toku Eyes has quickly distinguished itself in the MedTech field by integrating advanced technology with health care. The company’s flagship products, CLAiR and MyKidneyAI, utilise AI to analyse retinal images for signs that predict cardiovascular and kidney ailments. These tools have not only earned FDA breakthrough device designations but have also significantly impacted the way health care providers approach preventive care.

Ehsan's entrepreneurial spirit is demonstrated by his ability to secure substantial venture capital funding of around 11 million USD in total, including significant investments from major US-based entities like National Vision and Topcon Healthcare. These partnerships have been crucial in propelling Toku Eyes into the global market, making advanced diagnostic tools accessible and affordable.

These comprehensive health screenings are now part of routine eye exams in several countries, aimed at populations who traditionally have limited access to primary healthcare services. Dr. Ehsan Vaghefi's work is changing the landscape of healthcare, ensuring that preventive measures are not only a vision but a reality for all.